Dean Slagel has 23 years of biotechnology and pharmaceutical industry experience and an MBA from ENPC Paris. Starting in international marketing at Tillotts Pharma in Switzerland, he spent 10 years with the Ferring Group in regional operations management and global business development management based in the UK, Denmark and France. He has managed Esperante since 2004, during which time he has been responsible for building a 21 company investment portfolio in the USA, UK, France, Israel and Switzerland to date. During this period, Esperante has completed two successful exits (Thiakis and Pinnacle Biologics) and one IPO (Cara). Mr Slagel is currently a Director on the Boards of Altacor, Atox Bio, Cara Therapeutics, Canbex Therapeutics and Urosens.